<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812135</url>
  </required_header>
  <id_info>
    <org_study_id>EV71-1001-II-02</org_study_id>
    <nct_id>NCT01812135</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants</brief_title>
  <official_title>A Double-blind and Randomized, Phase II -02 Study With Inactivated EV71 Vaccines in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, phase II-02 clinical trial is to evaluate the safety and
      immunogenicity of an inactivated EV71 vaccine with or without aluminum adjuvant
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was
    elected to be used for the efficacy Phase III study.
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutralization antibody geometric mean titer in infants 28 days after immunization with 400U vaccine with or without aluminium hydroxide adjuvant</measure>
    <time_frame>2 months</time_frame>
    <description>Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus &gt;= 1:8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rates and severity of solicited and unsolicited adverse events in infants following immunization as a Measure of Safety and Tolerability</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Infection, Viral, Enterovirus</condition>
  <arm_group>
    <arm_group_label>Group 1: 400U EV71 vaccine without adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 400U EV71 vaccine without adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 400U EV71 vaccine with adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>400 U EV71 vaccine with adjuvant</intervention_name>
    <description>400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant</description>
    <arm_group_label>Group 1: 400U EV71 vaccine without adjuvant</arm_group_label>
    <arm_group_label>Group 2: 400U EV71 vaccine without adjuvant</arm_group_label>
    <arm_group_label>Group 3: 400U EV71 vaccine with adjuvant</arm_group_label>
    <other_name>EV71 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females, aged from 6 to 11 months old Health is determined by
             medical history, physical examination, laboratory examination and clinical judgment of
             the investigator

          2. Provided legal identification for the sake of recruitment.

          3. Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed
             consents.

          4. Birth weight more than 2500 grams

        Exclusion Criteria:

          1. History of Hand-foot-mouth Disease

          2. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine

          3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory
             difficulty, angioedema, or abdominal pain

          4. Congenital malformations or developmental disorders, genetic defects, or severe
             malnutrition

          5. Epilepsy, seizures or convulsions history, or family history of mental illness

          6. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have
             autoimmune diseases or immunodeficiency

          7. History of asthma, angioedema, diabetes or malignancy

          8. History of thyroidectomy or thyroid disease that required medication within the past
             12 months

          9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with IM injections or blood draws

         10. Asplenia, functional asplenia or any condition resulting in the absence or removal the
             spleen

         11. Acute illness or acute exacerbation of chronic disease within the past 7 days

         12. Any history of immunosuppressive medications or cytotoxic medications or inhaled
             corticosteroids within the past six months (with the exception of corticosteroid nasal
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated
             dermatitis)

         13. History of any blood products within 3 months

         14. Administration of any live attenuated vaccine within 28 days

         15. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or
             allergy treatment within 14 days

         16. Axillary temperature &gt; 37.0 centigrade before vaccination

         17. Abnormal laboratory parameters before vaccination

         18. Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-pin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GuangXi Center for Diseases Control and Prevention</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2013</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterovirus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

